ReviewMolecular diagnosis & therapy2013
Monitoring survivin expression in cancer: implications for prognosis and therapy.
Review in Molecular diagnosis & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2014Trial
- Article
- TheViruses · 2024Article
- Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.Pharmaceutics · 2022Review
- Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.BMC cancer · 2021Article
- Discovery of Survivin Inhibitors Part 1: Screening the Harbor Branch Pure Compound Library.Marine drugs · 2021Article
- Astrocytes Decreased the Sensitivity of Glioblastoma Cells to Temozolomide and Bay 11-7082.International journal of molecular sciences · 2020Article
- Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2018Article
- Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs.Clinical and translational medicine · 2017Article
- Adipose Tissue Metabolism and Cancer Progression: Novel Insights from Gut Microbiota?Current pathobiology reports · 2017Review
- DNA damage and the balance between survival and death in cancer biology.Nature reviews. Cancer · 2016Review
- Article
- Oral epithelial stem cells - implications in normal development and cancer metastasis.Experimental cell research · 2014Review
- Smoking in combination with antibodies to cyclic citrullinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: a prospective cohort study.Arthritis research & therapy · 2014Article
- Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agentsOncology letters · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survivin, a member of the inhibitor of apoptosis protein family, is one of the most cancer-specific proteins identified to date. Survivin expression is low or undetectable in most adult tissues, but, alternatively, is overexpressed in a large number of tumors. This multifunctional protein is recognized as a key regulator in apoptosis, proliferation and angiogenesis in the tumor environment. Several studies have shown a correlation between survivin upregulation and poor cancer prognosis, and, as expected, its downregulation or inactivation leads to inhibition of tumor growth. Therefore, survivin has attracted increasing attention both as a potential cancer biomarker and as a new target for anticancer therapies. This review summarizes and discusses survivin expression and its potential as a prognostic and diagnostic biomarker in different types of tumors, as well as provides an overview of the current therapeutic challenges of targeting survivin as a treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.